Comparative study of olopatadine 0.1% and lodoxamide 0.1% in treatment of seasonal allergic conjunctivitis

Abstract EN

Objective : olopatadine hydrochloride 0.1 % ophthalmic solution and Lodoxamide 0.1 % ophthalmic solution are two topical anti-allergic medications with slightly different modes of action.

This study compared the efficacy, tolerability and safety of these agents in the treatment of allergic conjunctivitis Methods : this was a three weeks prospective, randomized, double-masked, active-controlled, parallel group comparison study of Olopatadine hydrochloride 0.1 % ophthalmic solution (Patanol) and Lodoxamide 0.1 % (Alomide) in patients with seasonal allergic conjunctivitis.

Subjects were dosed twice daily for three weeks with either Olopatadine or Lodoxamide.

Signs and symptoms were assessed on day five (visit 2) and 21 (visit 3).

Efficacy variables included the responder rate (patient with excellent or good global efficacy on day 5 and 21), signs and symptoms, and patient and investigator-rated global efficacy.

Comfort was rated immediately after instillation of the first drop and at each follow-up visit.

Frequency of adverse events was the safety assessment.

Results: The study enrolled 66 patients, and 63 patients completed the study.

The responder rate was higher with Olopatadine than with Lodoxamide on both fifth day (72 % vs 54 % for patient assessment and 88 % vs.

55 % for investigator assessment), and day 21 (91 % vs.

55 % for patient assessment and 94 % vs.

42 % for investigator assessment).

Global efficacy ratings were higher for Olopatadine–treated subjects than Lodoxamide–treated patients.

Severity scores for hyperemia and itching were significantly lower for Olopatadine-treated group.

Comfort ratings were comparable between the two treatment groups.

Common adverse events included burning / stinging and headache.

Conclusion : olopatadine hydrochloride was superior in treating the signs and symptoms of allergic conjunctivitis.

Both treatments were safe and well tolerated.